text: Kadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease | BioSpace
  Application Being Reviewed Under FDA's Real-Time Oncology Review (RTOR) Pilot Program
  https://www.accesswire.com/608562/Kadmon-Announces-Submission-of-New-Drug-Application-to-the-US-FDA-for-Belumosudil-in-Patients-with-Chronic-Graft-Versus-Host-Disease